====== Bevacizumab (BEV) ======

{{rss>https://pubmed.ncbi.nlm.nih.gov/rss/search/1ZgpD-MkcZwiP-FpYDK6mScQNvA1D6bojINqoNUZAbsMACHY8n/?limit=15&utm_campaign=pubmed-2&fc=20250612201504}}

{{ ::bevacizumab.jpg?200|}}

[[Bevacizumab]] is a [[monoclonal antibody]] that inhibits [[angiogenesis]] by clearing circulating [[VEGF]], resulting in a decline in the contrast-enhancing tumor, which does not always correlate with treatment response.

Bevacizumab, as antibodies, were applied to inhibit tumor angiogenesis by preventing activation of vascular endothelial growth factor receptor. 

Bevacizumab, is sold under the trade name [[Avastin]] (Genentech/ Roche, South San Francisco, California).



===== Indications =====

[[Bevacizumab for glioblastoma]]

Bevacizumab for [[diffuse intrinsic pontine glioma]]



====Meningioma====
see [[Bevacizumab for meningioma]]

====Neurofibromatosis type 2====

see [[Bevacizumab for neurofibromatosis type 2]]

====Radiation induced necrosis====
[[Radiation induced necrosis]] in the brain has been treated using [[bevacizumab]]. 

Perez-Torres et al. validated the [[VEGF]] specificity by comparing the therapeutic efficacy of anti-VEGF with non-specific isotype control antibody. Additionally, they found that VEGF over-expression and [[radionecrosis]] developed simultaneously, which precludes preventative anti-VEGF treatment
((Perez-Torres CJ, Yuan L, Schmidt RE, Rich KM, Drzymala RE, Hallahan DE,
Ackerman JJ, Garbow JR. Specificity of vascular endothelial growth factor
treatment for radiation necrosis. Radiother Oncol. 2015 Sep 12. pii:
S0167-8140(15)00462-4. doi: 10.1016/j.radonc.2015.09.004. [Epub ahead of print]
PubMed PMID: 26376163.
)).

====Resistance====

Combining [[VEGF]] blockade with inhibition of [[Angiopoietin 2]] may potentially overcome resistance to [[bevacizumab]] therapy
((Scholz A, Harter PN, Cremer S, Yalcin BH, Gurnik S, Yamaji M, Di Tacchio M,
Sommer K, Baumgarten P, Bähr O, Steinbach JP, Trojan J, Glas M, Herrlinger U,
Krex D, Meinhardt M, Weyerbrock A, Timmer M, Goldbrunner R, Deckert M, Braun C,
Schittenhelm J, Frueh JT, Ullrich E, Mittelbronn M, Plate KH, Reiss Y.
Endothelial cell-derived angiopoietin-2 is a therapeutic target in
treatment-naive and bevacizumab-resistant glioblastoma. EMBO Mol Med. 2015 Dec
14. pii: e201505505. doi: 10.15252/emmm.201505505. [Epub ahead of print] PubMed
PMID: 26666269.
)).

===== References =====